Anika Therapeutics, Inc.
ANIK
$9.76
-$0.12-1.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 112.81M | 114.55M | 117.05M | 119.91M | 86.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 112.81M | 114.55M | 117.05M | 119.91M | 86.41M |
| Cost of Revenue | 50.45M | 48.37M | 44.74M | 43.30M | 21.76M |
| Gross Profit | 62.36M | 66.18M | 72.31M | 76.60M | 64.65M |
| SG&A Expenses | 48.33M | 50.00M | 53.39M | 55.56M | 28.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.60M | 123.19M | 123.33M | 124.40M | 66.10M |
| Operating Income | -11.80M | -8.65M | -6.28M | -4.50M | 20.31M |
| Income Before Tax | -10.03M | -7.47M | -4.72M | -2.77M | 22.48M |
| Income Tax Expenses | 4.23M | 5.46M | 6.11M | 6.06M | 12.59M |
| Earnings from Continuing Operations | -14.27 | -12.94 | -10.83 | -8.83 | 9.89 |
| Earnings from Discontinued Operations | -18.77M | -47.69M | -45.91M | -47.56M | -28.18M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.04M | -60.63M | -56.74M | -56.39M | -97.52M |
| EBIT | -11.80M | -8.65M | -6.28M | -4.50M | 20.31M |
| EBITDA | -5.35M | -3.47M | -304.00K | 1.95M | 28.13M |
| EPS Basic | -2.28 | -4.14 | -3.87 | -3.84 | -6.64 |
| Normalized Basic EPS | -0.41 | -0.30 | -0.18 | -0.09 | 0.96 |
| EPS Diluted | -2.29 | -4.15 | -3.88 | -3.84 | -6.64 |
| Normalized Diluted EPS | -0.41 | -0.30 | -0.18 | -0.09 | 0.96 |
| Average Basic Shares Outstanding | 57.66M | 58.01M | 58.48M | 58.88M | 58.96M |
| Average Diluted Shares Outstanding | 57.86M | 58.21M | 58.54M | 58.95M | 58.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |